<DOC>
	<DOC>NCT01215786</DOC>
	<brief_summary>This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.</brief_summary>
	<brief_title>Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension or primary openangle glaucoma in each eye Requires IOPlowering therapy in both eyes Visual acuity score of 20/100 or better in each eye Experienced significant weight change (over 10 pounds) within 60 days History of alcohol or drug addiction History of migraines or frequent headaches Anticipated wearing of contact lenses during the study Required chronic use of ocular medications during study Eye surgery within 6 months Use of systemic beta blockers (eg, atenolol, propranolol) within 2 months Use of oral, intramuscular, intravenous corticosteroids within 21 days Use of ophthalmic corticosteroids within 2 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>